Patrick Burnett, See Remarks at Arcutis Biotherapeutics, Inc. (ARQT), sold 12,957 shares at $24.71 ($313K) on 2025-11-03, disclosed to the SEC on 2025-11-05.
Scheduled sale ($313k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.71 | 2,607 | $64K | 20.6% |
| 2 | $24.71 | 2,607 | $64K | 20.6% |
| 3 | $25.40 | 15 | $381 | 0.1% |
| 4 | $23.72 | 3,864 | $92K | 29.3% |
| 5 | $23.72 | 3,864 | $92K | 29.3% |
| Total | $24.12 avg | 12,957 |
| $313K |
| 100% |
| Filing → |
| ARQT | SELL | 2026-08-05 | $25K | — | Filing → |
| ARQT | SELL | 2026-05-13 | $5K | — | Filing → |
| ARQT | SELL | 2026-05-06 | $16K | — | Filing → |